Home
Resources
Publications
Myasthenia Gravis and Specific Immunotherapy: Monoclonal Antibodies

Myasthenia Gravis and Specific Immunotherapy: Monoclonal Antibodies

Xiao-Jun Cai, Zai-Wang Li, Jian-Ying Xi, Hui-Zhu Song, Jue Liu, Wen-Hua Zhu, Yi Guo, Zheng Jiao

Ann N Y Acad Sci. 2019 Sep;1452(1):18-33.

PMID: 31393614

Abstract:

Myasthenia gravis (MG) is an acquired autoimmune disease affecting the postsynaptic membrane of neuromuscular junctions and characterized by antibody-mediated T cell dependence and complement involvement. Cholinesterase inhibitors (e.g., pyridostigmine bromide), glucocorticoids, and azathioprine are currently recommended as first-line treatments for MG, though they have limitations, including potential toxicity and ineffectiveness in patients with refractory MG. In recent years, owing to an increasing understanding of MG pathogenesis the development and execution of clinical trials with novel biologics, including monoclonal antibodies (mAbs) that have demonstrated higher safety and more specificity, provide new opportunities for the treatment of MG. In this article, we review recent advances in MG pathogenesis and the mAbs that have been used for target-specific MG therapy.

Chemicals Related in the Paper:

Catalog Number	Product Name	Structure	CAS Number	Price
AP101268-A	Pyridostigmine bromide		101-26-8	Price

As a specialist in analytical chemical Products, Alfa Chemistry offers consumers a wealth of raw materials and a full range of technologies and services.

QUICK LINKS

HEADQUARTERS

Tel:

Fax:

Email: